Connect with us

BIOTECH

AbbVie Inc (NYSE:ABBV) Q2 2017 Worldwide Net Revenues Surges 7.6%

Published

on

AbbVie Inc (NYSE:ABBV) released financial report for the second quarter closed June 30, 2017. Richard A. Gonzalez, the CEO and Chairman, reported that they are delighted with the sustained strength of their business. The second quarter financial performance reflects strong operational and commercial execution.

The CEO added that they remain extremely encouraged about the recent development they have made with their late-stage pipeline, including impressive results from a registrational study of their selective JAK1 inhibitor, named upadacitinib. They look forward to witnessing data from different additional pivotal trials in the second half of this year.

The performance

AbbVie reported that worldwide net revenues in 2Q 2017 came at $6.944 billion, up 7.6% YoY, on a GAAP basis. Adjusted net revenues, on operational basis, surged 8.9%, excluding a 0.9% unfavorable impact from foreign exchange. In Q2 2017, Global HUMIRA sales jumped 13.7% on a reported basis, or 14.9% operationally, discounting a 1.2% unfavorable impact from foreign exchange.

AbbVie reported that in the United States, HUMIRA sales surged 18% in the quarter. Globally, HUMIRA sales jumped 9.1%, excluding a 3.6% unfavorable impact from foreign exchange. Net revenues of Global IMBRUVICA in Q2 2017 came at $626 million, with sales in United States coming at s$528 million and global profit sharing of $98 million for the second quarter, showing growth of 42.6%.

The gross margin ratio came at 78% while the adjusted gross margin ratio stood at 82.3%. S,G&A expense constituted 21.7% of net revenues. R&D expense constituted 17.6% of net revenues while on adjusted basis, it was 17.5%, highlighting funding actions supporting all phases of company’s pipeline.

AbbVie reported that it expects GAAP diluted EPS for FY2017 to come in between $4.55 and $4.65. The company projects to deliver adjusted diluted earnings for FY2017 of $5.44 to $5.54 per share, indicating growth of 13.9% at the mid-point.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of MMJReporter.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure

BRANDS

DETAILS

SCORE

PRODUCT SITES

  • Certified Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49

9.8

30% OFF Today! “30 0FF”

  • All Natural
  • Made In U.S.A
  • Lab Tested
  • Price From $69

9.7

  • All Natural
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99

9.6

  • All Natural
  • Made In U.S.A
  • Oral Mist
  • Price From $39

9.5

BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49
SCORE

9.8

PRODUCT SITE
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Lab Tested
  • Price From $69
SCORE

9.7

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99
SCORE

9.6

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Oral Mist
  • Price From $39
SCORE

9.5

PRODUCT SITE VIEW PRODUCTS
Advertisement

Title

Uncategorized2 days ago

Top 15 Essential Oils + Health Benefits

Top 15 Essential Oils + Health Benefits Each and every essential oil contains compounds with unique healing and therapeutic benefits....

Uncategorized2 days ago

Using Hemp Oil in Cooking

Hemp oil has many advocates. The oil from hemp seeds is rich in omega-3 and omega-6 essential fatty acids. This makes...

Uncategorized6 days ago

Best Oil Producers of 2018

Millionaires are being made by the moment in the medical marijuana industry. Venture capital firms, private equity firms, and even...

MyDx Inc MyDx Inc
Health3 weeks ago

MyDx Inc. (OTCMKTS:MYDX) Initiates Clinical Trial of Cannabis Formula for The Treatment of Chronic Low Back Pain

San Diego, CA based MyDx Inc. (OTCMKTS:MYDX) has announced the controlled trial of the cannabis formula for the treatment of...

Business3 weeks ago

Fastfunds Financial Corporation (OTCMKTS:FFFC) Is All Set to Launch Affinity Connextions Program Targeting MMJ Industry

Fastfunds Financial Corporation (OTCMKTS:FFFC) has announced the completion of all necessary formalities to introduce an Affinity Connextions Program through a...

Innovative Industrial Properties Inc Innovative Industrial Properties Inc
Business3 weeks ago

Innovative Industrial Properties, Inc (NYSE:IIPR) Unveils Exercise Of Underwriter’s Option To Purchase Common Stock Shares

Innovative Industrial Properties, Inc (NYSE:IIPR) announced recently that it has obtained the exercise of the underwriter’s option to buy additional...

Business3 weeks ago

Next Generation Management Corporation (OTCMKTS:NGMC) Updates On New Medical Marijuana System in Oregon

Nextgen Holdings, a subsidiary of the Next Generation Management Corporation (OTCMKTS:NGMC) recently updated its stockholders with the ongoing Medical Marijuana...

INDUSTRIAL HEMP3 weeks ago

Weed Inc’s (OTCMKTS:BUDZ) Performance Is Getting Higher

Weed Inc (OTCMKTS:BUDZ) has for a long time been enjoying the momentous highs for the past few months. The company’s...

INDUSTRIAL HEMP3 weeks ago

Namaste Technologies Inc (OTCMKTS:NXTTF) Signs A Share Purchase Agreement With Cannbit Ltd

Namaste Technologies Inc (OTCMKTS:NXTTF) announced recently that it signed a non-binding Letter of Intent (LOI) with Cannabit Limited where the...

INDUSTRIAL HEMP3 weeks ago

MariMed Inc. (OTCMKTS:MRMD) Plans To Expand Its Cannabis Business

MeriMed Inc. (OTCMKTS:MRMD) announced its grand plans to expand business into the emerging cannabis industry. Furthermore, the company intends to...

Advertisement
Advertisement
Advertisement